IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0781 -0,0003 (-0,03%) Petróleo Brent
82,94 -0,94 (-1,12%) Oro
2.376,20 +35,90 (+1,53%) Bitcoin EUR
56.504,62 -951,04 (-1,66%)
Amgen Inc. (0R0T.IL)
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com
Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 25.200
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Robert A. Bradway | Chairman, CEO & Pres | 5,49M | N/A | 1963 |
| Mr. Peter H. Griffith | Exec. VP & CFO | 2,57M | N/A | 1959 |
| Mr. Esteban Santos | Exec. VP of Operations | 2,52M | N/A | 1968 |
| Dr. David M. Reese M.D. | Exec. VP of R&D | 2,83M | N/A | 1963 |
| Mr. Murdo Gordon | Exec. VP of Global Commercial Operations | 2,72M | N/A | 1967 |
| Mr. Matthew C. Busch | Chief Accounting Officer & VP of Fin. | N/A | N/A | 1974 |
| Mr. Mike Zahigian | Sr. VP & Chief Information Officer | N/A | N/A | N/A |
| Mr. Arvind Sood | VP of Investor Relations | N/A | N/A | N/A |
| Mr. Jonathan P. Graham | Exec. VP, Gen. Counsel & Sec. | N/A | N/A | 1961 |
| Ms. Nancy A. Grygiel | Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer | N/A | N/A | 1968 |
Descripción
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Gobierno corporativo
El ISS Governance QualityScore de Amgen Inc., a día 1 de octubre de 2023, es 3. Las puntuaciones base son Auditoría: 4; Tablero: 9; Derechos de los accionistas: 1; Compensación: 3.
